Table 1.

Summary of the included studies

Study ID	Study Design	Country	Recruitment duration	Total sample size, N	Dosages (mg/kg)		Timing after symptoms onset
					Tenecteplase	Alteplase
Bivard et al. 2022 [19]	Phase 2, single center, PROBE	Australia	From June 2019 to November 2021	N = 104	(0·25 mg/kg)	(0·9 mg/kg)	4.5 h
Campbell et al. 2018 [35]	Phase 2, multicenter, PROBE	Australia and New Zealand	From March 2015 to October 2017	N = 202	(0·25 mg/kg)	(0·9 mg/kg)	4.5 h
Haley et al. 2010 [36]	Phase 2B/3, multicenter, double-blinded, prematurely terminated RCT	USA	From March 2006 to December 2008	N = 112	Group 1 = 0.1 mg/kg Group 2 = 0.25 mg/kg Group 3 = 0.4 mg/kg	(0.9 mg/kg)	3 h
Huang et al. 2015 [34]	Phase 2, single center, PROBE	Scotland	From January 2012 to September 2013	N = 96	(0·25 mg/kg)	(0·9 mg/kg)	4.5 h
Kvistad et al. 2022 [21]	Phase 3, multicenter, PROBE	Norway	From October 2019 to September 2021	N = 204	(0·4 mg/kg) [maximum 40 mg]	(0·9 mg/kg)	4.5 h
Li et al. 2021 [23]	Phase 2, multicenter, PROBE	China	From May 2018 to February 2020	N = 236	Group 1 = 0.1 mg/kg Group 2 = 0.25 mg/kg Group 3 = 0.32 mg/kg	(0·9 mg/kg)	3 h
Logallo et al. 2017 [37]	Phase 3, multicenter, PROBE	Norway	From September 2012 to September 2016	N = 1,100	(0·4 mg/kg)	(0·9 mg/kg)	4.5 h
Menon et al. 2022 [22]	Phase 3, multicenter, PROBE	Canada	From December 2019 to January 2022	N = 1,577	(0·25 mg/kg)	(0·9 mg/kg)	4.5 h
Parsons et al. 2012 [38]	Phase 2B, multicenter, PROBE	Australia	From 2008 to 2011	N = 75	Group 1 = 0.1 mg/kg Group 2 = 0.25 mg/kg	(0·9 mg/kg)	less than 6 h

PROBE prospective, randomized, open-label, blinded outcome study, RCT randomized controlled trial, N number, mg milligram, kg kilogram